171 related articles for article (PubMed ID: 24504051)
21. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia.
Chen DW; Saha V; Liu JZ; Schwartz JM; Krstic-Demonacos M
Oncogene; 2013 Jun; 32(25):3039-48. PubMed ID: 22869147
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
23. MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation.
Huang Y; Thoms JA; Tursky ML; Knezevic K; Beck D; Chandrakanthan V; Suryani S; Olivier J; Boulton A; Glaros EN; Thomas SR; Lock RB; MacKenzie KL; Bushweller JH; Wong JW; Pimanda JE
Leukemia; 2016 Jul; 30(7):1552-61. PubMed ID: 27055868
[TBL] [Abstract][Full Text] [Related]
24. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N
Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071
[TBL] [Abstract][Full Text] [Related]
25. ERG Expression is Helpful in Differentiating T-Lymphoblastic Lymphoma from Thymoma.
Huang W; Zhang W; Zeng L; Liao S; Liu F; Li L
Int J Surg Pathol; 2023 Apr; 31(2):137-141. PubMed ID: 35435050
[TBL] [Abstract][Full Text] [Related]
26. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
Han S; Brenner JC; Sabolch A; Jackson W; Speers C; Wilder-Romans K; Knudsen KE; Lawrence TS; Chinnaiyan AM; Feng FY
Neoplasia; 2013 Oct; 15(10):1207-17. PubMed ID: 24204199
[TBL] [Abstract][Full Text] [Related]
27. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Mahon FX; Hayette S; Lagarde V; Belloc F; Turcq B; Nicolini F; Belanger C; Manley PW; Leroy C; Etienne G; Roche S; Pasquet JM
Cancer Res; 2008 Dec; 68(23):9809-16. PubMed ID: 19047160
[TBL] [Abstract][Full Text] [Related]
28. A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR/PI3K/Akt expression.
Banerjee K; Das S; Sarkar A; Chatterjee M; Biswas J; Choudhuri SK
Biomed Pharmacother; 2016 Dec; 84():71-92. PubMed ID: 27639544
[TBL] [Abstract][Full Text] [Related]
29. The proto-oncogene ERG in megakaryoblastic leukemias.
Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
[TBL] [Abstract][Full Text] [Related]
30. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
Kao CJ; Martiniez A; Shi XB; Yang J; Evans CP; Dobi A; deVere White RW; Kung HJ
Oncogene; 2014 May; 33(19):2495-503. PubMed ID: 23728339
[TBL] [Abstract][Full Text] [Related]
31. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.
Tesfai Y; Ford J; Carter KW; Firth MJ; O'Leary RA; Gottardo NG; Cole C; Kees UR
Leuk Res; 2012 Mar; 36(3):299-306. PubMed ID: 21889797
[TBL] [Abstract][Full Text] [Related]
32. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.
Ariës IM; Bodaar K; Karim SA; Chonghaile TN; Hinze L; Burns MA; Pfirrmann M; Degar J; Landrigan JT; Balbach S; Peirs S; Menten B; Isenhart R; Stevenson KE; Neuberg DS; Devidas M; Loh ML; Hunger SP; Teachey DT; Rabin KR; Winter SS; Dunsmore KP; Wood BL; Silverman LB; Sallan SE; Van Vlierberghe P; Orkin SH; Knoechel B; Letai AG; Gutierrez A
J Exp Med; 2018 Dec; 215(12):3094-3114. PubMed ID: 30404791
[TBL] [Abstract][Full Text] [Related]
33. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
[TBL] [Abstract][Full Text] [Related]
34. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
[TBL] [Abstract][Full Text] [Related]
35. Deletion of the Miz-1 POZ Domain Increases Efficacy of Cytarabine Treatment in T- and B-ALL/Lymphoma Mouse Models.
Ross J; Rashkovan M; Fraszczak J; Joly-Beauparlant C; Vadnais C; Winkler R; Droit A; Kosan C; Möröy T
Cancer Res; 2019 Aug; 79(16):4184-4195. PubMed ID: 31273062
[TBL] [Abstract][Full Text] [Related]
36. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults.
Baldus CD; Burmeister T; Martus P; Schwartz S; Gökbuget N; Bloomfield CD; Hoelzer D; Thiel E; Hofmann WK
J Clin Oncol; 2006 Oct; 24(29):4714-20. PubMed ID: 16954520
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.
Singareddy R; Semaan L; Conley-Lacomb MK; St John J; Powell K; Iyer M; Smith D; Heilbrun LK; Shi D; Sakr W; Cher ML; Chinni SR
Mol Cancer Res; 2013 Nov; 11(11):1349-61. PubMed ID: 23918819
[TBL] [Abstract][Full Text] [Related]
38. Selective dysregulation of ABC transporters in methotrexate-resistant leukemia T-cells can confer cross-resistance to cytarabine, vincristine and dexamethasone, but not doxorubicin.
Aberuyi N; Rahgozar S; Pourabutaleb E; Ghaedi K
Curr Res Transl Med; 2021 Jan; 69(1):103269. PubMed ID: 33071214
[TBL] [Abstract][Full Text] [Related]
39. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
[TBL] [Abstract][Full Text] [Related]
40. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
